Citius Pharmaceuticals (CTXR) Notes Payables (2011 - 2025)
Citius Pharmaceuticals' (CTXR) quarterly Notes Payables came in at $1.0 million in Q4 2025, little changed on a QoQ basis from $1.0 million in Q3 2025.
Citius Pharmaceuticals (CTXR) Notes Payables (2011 - 2025) Analysis & Trends
Citius Pharmaceuticals (CTXR) has 12 years of Notes Payables data on file, last reported at $1.0 million in Q4 2025.
- Quarterly Notes Payables changed N/A year-over-year to $1.0 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $1.0 million (changed N/A YoY) and the FY2025 annual result came in at $1.0 million, changed N/A from the prior year.
- Notes Payables held at $1.0 million in Q4 2025, from $1.0 million in the prior quarter.
- In the past five years, Notes Payables ranged from a high of $1.0 million in Q2 2025 to a low of $172970.0 in Q1 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.90 Bn | 131.05 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 86.10 Bn | 78.11 Bn | 3.93 Bn |
| 3 | Argenx Se | 65.56 Bn | 60.37 Bn | 1.37 Bn |
| 4 | Moderna | 55.82 Bn | 50.68 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 42.14 Bn | 37.04 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.67 Bn | 28.36 Bn | 992.69 Mn |
| 7 | BioNTech SE | 27.74 Bn | 9.35 Bn | 668.28 Mn |
| 8 | Insmed | 27.53 Bn | 26.37 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.38 Bn | 26.54 Bn | - |
| 10 | Citius Pharmaceuticals | 15.97 Mn | 15.97 Mn | 1.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 1.00 Mn |
| Sep 30, 2025 | 1.00 Mn |
| Jun 30, 2025 | 1.00 Mn |
| Mar 31, 2021 | 172,970.00 |
| Dec 31, 2020 | 172,970.00 |
| Sep 30, 2020 | 172,970.00 |
| Jun 30, 2020 | 172,970.00 |
| Mar 31, 2020 | 172,970.00 |
| Dec 31, 2019 | 172,970.00 |
| Sep 30, 2019 | 172,970.00 |
| Jun 30, 2019 | 172,970.00 |
| Mar 31, 2019 | 172,970.00 |
| Dec 31, 2018 | 172,970.00 |
| Sep 30, 2018 | 172,970.00 |
| Jun 30, 2018 | 172,970.00 |
| Mar 31, 2018 | 172,970.00 |
| Dec 31, 2017 | 172,970.00 |
| Sep 30, 2017 | 172,970.00 |
| Jun 30, 2017 | 581,164.00 |
| Mar 31, 2017 | 772,970.00 |